1. CDER introduces measures to reduce risk of stimulant use disorder

   News item 21 October 2023 Pages: 1 - 1

2. Compounded ketamine products: potential risks of at-home use

   News item 21 October 2023 Pages: 2 - 2

3. Isotretinoin-related psychiatric disorders and sexual dysfunction

   News item 21 October 2023 Pages: 3 - 3

4. No new or worrying AEs after influenza or pneumococcal vaccination

   News item 21 October 2023 Pages: 4 - 4

5. UK patients to receive valproate safety information with every pack

   News item 21 October 2023 Pages: 5 - 5

6. Cabozantinib + nivolumab and ipilimumab/nivolumab have differing safety profiles

   Clinical study 21 October 2023 Pages: 6 - 6

7. HER2-targeted antibody-drug conjugates: no increase in risk of fatal AEs

   Clinical study 21 October 2023 Pages: 7 - 7

8. HLA-B*13:01 screening not cost effective prior to cotrimoxazole use

   Clinical study 21 October 2023 Pages: 8 - 8

9. Opioid analgesic-related ADRs

   Clinical study 21 October 2023 Pages: 9 - 9

10. PARP inhibitors: risk of haematological toxicities

    Clinical study 21 October 2023 Pages: 10 - 10

11. Provision of opioids for musculoskeletal pain in the ED: risk of continued opioid use

    Review 21 October 2023 Pages: 11 - 11

12. Some drug classes increase risk of poor driving performance

    Clinical study 21 October 2023 Pages: 12 - 12

13. Other adverse reaction research

    News item 21 October 2023 Pages: 13 - 13

14. Mitragyna-speciosa

    Case report 21 October 2023 Pages: 14 - 14

15. Aciclovir/antiepileptic drugs/dexamethasone

    Case report 21 October 2023 Pages: 15 - 15

16. Aconitum

    Case report 21 October 2023 Pages: 16 - 16

17. Ad26.COV2-S

    Case report 21 October 2023 Pages: 17 - 17

18. Adalimumab

    Case report 21 October 2023 Pages: 18 - 18

19. Adenosine

    Case report 21 October 2023 Pages: 19 - 19

20. Alemtuzumab

    Case report 21 October 2023 Pages: 20 - 20

21. Alfacalcidol/phosphorus

    Case report 21 October 2023 Pages: 21 - 21

22. Alpelisib/letrozole/palbociclib

    Case report 21 October 2023 Pages: 22 - 22

23. Alteplase

    Case report 21 October 2023 Pages: 23 - 23

24. Alteplase

    Case report 21 October 2023 Pages: 24 - 24

25. Aluminium-hydroxide/magnesium/epinephrine/lidocaine

    Case report 21 October 2023 Pages: 25 - 25

26. Aluminium-potassium-sulfate misuse

    Case report 21 October 2023 Pages: 26 - 26

27. Amiodarone

    Case report 21 October 2023 Pages: 27 - 27

28. Amiodarone

    Case report 21 October 2023 Pages: 28 - 28

29. Amiodarone

    Case report 21 October 2023 Pages: 29 - 29

30. Amiodarone/glucagon/metoprolol

    Case report 21 October 2023 Pages: 30 - 30

31. Amiodarone/tozinameran

    Case report 21 October 2023 Pages: 31 - 31

32. Amisulpride

    Case report 21 October 2023 Pages: 32 - 32

33. Amisulpride/clozapine

    Case report 21 October 2023 Pages: 33 - 33

34. Amlodipine

    Case report 21 October 2023 Pages: 34 - 34

35. Amoxicillin

    Case report 21 October 2023 Pages: 35 - 35

36. Amphotericin B liposomal/dexamethasone/flucytosine

    Case report 21 October 2023 Pages: 36 - 36

37. Amphotericin-b-liposomal

    Case report 21 October 2023 Pages: 37 - 37

38. Amphotericin-b/flucytosine/prednisone

    Case report 21 October 2023 Pages: 38 - 38

39. Anagrelide

    Case report 21 October 2023 Pages: 39 - 39

40. Anakinra

    Case report 21 October 2023 Pages: 40 - 40

41. Anakinra

    Case report 21 October 2023 Pages: 41 - 41

42. Antibacterials

    Case report 21 October 2023 Pages: 42 - 42

43. Antibacterials/dexamethasone

    Case report 21 October 2023 Pages: 43 - 43

44. Antibacterials/opioid-analgesics

    Case report 21 October 2023 Pages: 44 - 44

45. Antidepressants and lorazepam

    Case report 21 October 2023 Pages: 45 - 45

46. Antineoplastics

    Case report 21 October 2023 Pages: 46 - 46

47. Antineoplastics

    Case report 21 October 2023 Pages: 47 - 47

48. Antineoplastics

    Case report 21 October 2023 Pages: 48 - 48

49. Antineoplastics

    Case report 21 October 2023 Pages: 49 - 49

50. Antineoplastics

    Case report 21 October 2023 Pages: 50 - 50